Clinical trial · Expanded Access
Oral Green Tea Extract for Small Cell Lung Cancer
Phase ⅠStudy of Oral Green Tea Extract as Maintenance Therapy for Extensive-stage Small Cell Lung Cancer
NCT01317953CI-TRIAL-00037952availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether green tea extract is safe for extensive-stage small lung cancer who achieved objective tumor response after first-line therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Carcinoma | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| epigallocatechin gallate | Dietary Supplement | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of small cell lung cancer * extensive-stage disease * Eastern Cooperative Oncology Group performance status (PS) of 0 to 2 * age18 years old * Adequate bone marrow reserves: neutrophil (ANC) count ≥ 1500 /mm\^3, platelet count ≥ 100,000 /mm\^3, hemoglobin ≥ 9 g/dl * Adequate renal function: serum creatinine ≤ 1.5 mg/dl and/or calculated creatinine clearance ≥ 60 ml/min * Adequate hepatic function: bilirubin level ≤ 1.5 x ULN, ASAT \& ALST ≤ 1.5 x ULN * Signed written informed consent prior to study entry * According to Response Evaluation Criteria in Solid Tumors(RECIST), patients didn't progress after first-line chemotherapy Exclusion Criteria: * Any condition that would hamper informed consent or ability to comply with the study protocol * Participation in another research study in the last three months * Known malignancy at any site other than SCLC * Recent consumption of green tea (5 or more cups per day within one week of study enrollment) * Pregnant and lactating women * History of allergic reactions attributed to compounds of similar chemical or biologic composition to EGCG
References
Publications (0)
Data not yet available
No reference posted for this study.